Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Core Insights - Vaxart, Inc. has received approval from BARDA to initiate dosing in a 10,000-participant Phase 2b clinical trial for its oral COVID-19 vaccine candidate [1][2] - The trial aims to evaluate the efficacy, safety, and immunogenicity of Vaxart's oral vaccine compared to an approved mRNA COVID-19 vaccine in previously vaccinated adults [2] - The project is part of Project NextGen, a $5 billion initiative to accelerate the development of innovative COVID-19 vaccines, with Vaxart's award valued at up to $460.7 million [3] Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform [4] - The company's vaccines are designed to be administered in pill form, eliminating the need for refrigeration and reducing the risk of needle-stick injuries [4] - Vaxart's development pipeline includes vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for HPV [4]